Diversified science and technology company Danaher (NYSE: DHR) fell short of the market’s revenue expectations in Q1 CY2026 as sales rose 3.7% year on year to $5.95 billion. Its non-GAAP profit of $2.06 per share was 6.4% above analysts’ consensus estimates.

Is now the time to buy DHR? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Danaher’s first quarter results for 2026 were met with a negative market response, as revenue failed to reach Wall Street’s expectations despite growth in several core areas. Management cited robust performance in bioprocessing and a stabilizing Life Sciences segment as key contributors, while noting that a lighter-than-usual respiratory season at Cepheid and ongoing pressure in Chinese diagnostics weighed on results. CEO Rainer Blair highlighted “gradual improvement in R&D spending” and pronounced resilience across commercial monoclonal antibody production, but acknowledged that some end-market headwinds have persisted longer than anticipated.

Looking ahead, Danaher’s updated outlook is anchored by expectations for continued bioprocessing strength, a rebound in Life Sciences, and the anticipated closing of the Masimo acquisition. Management believes that the integration of Masimo will create strategic synergies in acute care diagnostics and drive accretive earnings growth. CFO Matt Gugino emphasized that while some headwinds—particularly in China diagnostics and academic research—are likely to fade by year-end, the company’s guidance does not assume major market improvements. Blair stated, “We see a bright future ahead for Danaher,” pointing to the company’s position in emerging AI-driven laboratory automation and new product introductions as long-term growth drivers.

Key Insights from Management’s Remarks

Danaher’s management attributed first quarter performance to steady bioprocessing demand, incremental progress in Life Sciences, and targeted cost control, while ongoing softness in respiratory diagnostics and North American academic markets created challenges.

• Bioprocessing demand sustained: Management reported continued high single-digit growth in consumables, underpinned by robust global demand for commercialized biologic therapies and notable equipment order growth (>30% year over year). This improvement in the order book is seen as supportive of a longer-term bioprocessing investment cycle.

• Life Sciences stabilization: The Life Sciences segment experienced early signs of recovery, especially in consumables and in China, where improved funding and commercial execution at Aldevron and Abcam contributed to positive momentum. Management noted that academic research spending remains muted, though order activity is showing initial signs of improvement.

• Diagnostics headwinds persist: Core revenue in Diagnostics declined, driven by a softer respiratory season at Cepheid, and ongoing pricing pressures in China due to policy changes. Non-respiratory diagnostics, however, grew mid-single digits outside China, buoyed by new menu introductions and share gains in immunoassay and molecular diagnostics.

• Innovation and new products: Danaher launched several new products, including Cytiva’s Fibro dT mRNA purification platform and Beckman Coulter’s strategic partnership with Automata for AI-driven automation. The launch of the Xpert GI panel at Cepheid and FDA clearance for new immunoassay tests at Beckman Diagnostics were highlighted as contributors to future growth.

• Portfolio enhancement and M&A: The pending acquisition of Masimo was described as highly strategic, expected to create both cost and revenue synergies, particularly through integration with Radiometer. Management also highlighted a strong pipeline for further M&A, with a disciplined approach to capital deployment and a focus on secular growth markets.

Drivers of Future Performance

Management expects Danaher’s growth to accelerate over the coming quarters, supported by bioprocessing tailwinds, new product launches, and the addition of Masimo, though certain market headwinds remain present.

• Bioprocessing and Life Sciences recovery: The company anticipates that the moderation of respiratory and China diagnostics headwinds, coupled with sustained bioprocessing demand and recovering Life Sciences funding, will support a return to mid-single-digit core revenue growth by year-end. Management emphasized that improving order trends and investment cycles in bioprocessing equipment are central to this outlook.

• Masimo acquisition integration: The closing and integration of Masimo, a leader in pulse oximetry and acute care monitoring, is expected to deliver both cost and revenue synergies. Management projects Masimo to be accretive to earnings in its first year as part of Danaher, with high single-digit return on invested capital by year five, driven by cross-selling opportunities and operational efficiencies.

• AI and automation adoption: Danaher sees artificial intelligence as a secular tailwind, particularly in accelerating pharmaceutical development and laboratory automation. The company expects AI-enabled products and workflow tools to enhance customer productivity, drive higher demand for analytical instruments and consumables, and contribute to long-term margin expansion.

Catalysts in Upcoming Quarters

In upcoming quarters, our analysts will be monitoring (1) the pace at which bioprocessing equipment order growth translates into revenue, (2) the success of the Masimo integration and its impact on both margins and growth, and (3) further stabilization in Life Sciences and Diagnostics, particularly in China and academic research. New product adoption and AI-driven automation will also be important signposts for Danaher’s execution on its long-term strategy.

Danaher currently trades at $195.50, in line with $195.50 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.